Grande Legacy Inc. agreed to acquire Vitaxel Group Limited (OTCPK:VXEL) in a reverse merger transaction on December 15, 2017. Vitaxel Group Limited will issue 75 million shares as a consideration against the four shares of Grande Legacy Inc. for $0.4 per share. Lim Hui Sing and Leong Yee Ming will get 37.5 million shares each. These shares will represent 58.1% of Vitaxel Group Limited upon completion. If the documents required to be delivered on Completion are not forthcoming for any reason or if in any other respect are not fully complied with by any party to the transaction the other party shall be entitled to elect to terminate agreement without liability on its part in which event the defaulting party shall indemnify the non-defaulting party and keep the non-defaulting party indemnified against all fees and costs incurred by the non-defaulting party in the negotiation, preparation, execution or termination of agreement or the fulfillment of any of the conditions precedent and the rights and obligations of the purchaser and the vendors shall cease immediately on termination save for each party's accrued rights and obligations at the date of termination. The transaction is expected to complete within six months from this agreement date. On January 3, 2018, the parties to the agreement executed and delivered an amendment which provided that the acquisition of Grande Legacy shall close upon the completion of the financial statements of Grande Legacy being audited. The amendment also provides that the 75 million shares to be issued to the sellers will be issued within 30 days of the shareholders of Vitaxel Group Limited authorizing the amendment of Vitaxel Group Limited increasing the amount of shares that the Vitaxel Group Limited is authorized to issue. B F Borgers CPA PC acted as accountant in the transaction. Grande Legacy Inc. completed the acquisition of Vitaxel Group Limited (OTCPK:VXEL) in a reverse merger transaction on January 22, 2018.